OrganiGram Holdings  logo
OrganiGram Holdings OGI
$ 1.16 0.42%
report update icon

Quarterly report 2024-Q4
added 09-03-2026

OrganiGram Holdings Cash Flow 2024-2011 | OGI

Brief overview of OrganiGram Holdings 's cash flow quality

The comparison covers five available annual reports between 2020 and 2024.

Core operations moved from negative cash flow of -45.1 million CAD to an inflow of 3.9 million CAD, an important positive shift.

Only 1 of five annual observations were positive, indicating weak repeatability.

Operating cash margin reached 2.4% versus -52% initially. Revenue converted into cash more effectively.

Conclusion

OrganiGram Holdings 's cash flow is not clear-cut. Operating receipts exist, but their stability or the residual after investment needs attention.

Annual Cash Flow OrganiGram Holdings

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

3.87 M -38.8 M -36.2 M -28.6 M -45.1 M -35.1 M -12.7 M - - - - - - -

All numbers in CAD currency

Quarterly Cash Flow OrganiGram Holdings

2024-Q4 2024-Q3 2023-Q4 2023-Q3 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- 3.87 M - -38.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in CAD currency

Cash Flow Statement is one of the three key financial reports of the company OrganiGram Holdings , reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Drug manufacturers sector

Issuer Price % 24h Market Cap Country
PLx Pharma PLx Pharma
PLXP
- -27.8 % $ 2.56 M usaUSA
HEXO Corp. HEXO Corp.
HEXO
- 2.45 % $ 38.1 M canadaCanada
Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ)
CALT
- -0.1 % $ 2.03 B schwedenSchweden
Athenex Athenex
ATNX
- -23.39 % $ 1.76 M usaUSA
Sundial Growers Sundial Growers
SNDL
$ 1.44 1.77 % $ 372 M canadaCanada
Endo International plc Endo International plc
ENDP
- - $ 28.9 M irlandaIrlanda
Perrigo Company plc Perrigo Company plc
PRGO
$ 14.92 4.56 % $ 2.07 B usaUSA
Canopy Growth Corporation Canopy Growth Corporation
CGC
$ 0.97 0.17 % $ 289 M canadaCanada
Aurora Cannabis Aurora Cannabis
ACB
$ 3.95 1.54 % $ 217 M canadaCanada
Aerie Pharmaceuticals Aerie Pharmaceuticals
AERI
- - $ 754 M usaUSA
AcelRx Pharmaceuticals AcelRx Pharmaceuticals
ACRX
- 7.5 % $ 6.35 M usaUSA
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation
ADMP
- 0.86 % $ 117 M usaUSA
Agile Therapeutics Agile Therapeutics
AGRX
- 10.11 % $ 58.2 M usaUSA
Alimera Sciences Alimera Sciences
ALIM
- - $ 142 M usaUSA
Assertio Holdings Assertio Holdings
ASRT
- - $ 150 M usaUSA
Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc
AVDL
- - $ 2.06 B franceFrance
Bausch Health Companies Bausch Health Companies
BHC
$ 6.56 5.56 % $ 2.43 B canadaCanada
China Pharma Holdings China Pharma Holdings
CPHI
$ 0.82 0.1 % $ 3.52 M chinaChina
Cumberland Pharmaceuticals Cumberland Pharmaceuticals
CPIX
$ 6.79 0.59 % $ 101 M usaUSA
Cronos Group Cronos Group
CRON
$ 3.26 0.62 % $ 1.25 B canadaCanada
Catalent Catalent
CTLT
- - $ 11.5 B usaUSA
DURECT Corporation DURECT Corporation
DRRX
- - $ 50.1 M usaUSA
Emergent BioSolutions Emergent BioSolutions
EBS
$ 6.21 0.08 % $ 332 M usaUSA
Eagle Pharmaceuticals Eagle Pharmaceuticals
EGRX
- -39.89 % $ 27.7 M usaUSA
Evolus Evolus
EOLS
$ 9.3 2.76 % $ 600 M usaUSA
Evoke Pharma Evoke Pharma
EVOK
- - $ 36.6 M usaUSA
Harrow Health Harrow Health
HROW
$ 38.54 0.73 % $ 1.42 B usaUSA
Jupiter Wellness Jupiter Wellness
JUPW
- - $ 33.6 M usaUSA
Lannett Company Lannett Company
LCI
- 1.15 % $ 7.11 M usaUSA
Neoleukin Therapeutics Neoleukin Therapeutics
NLTX
- - $ 193 M canadaCanada
OptiNose OptiNose
OPTN
- - $ 1.08 B usaUSA
Organogenesis Holdings Organogenesis Holdings
ORGO
$ 1.71 4.27 % $ 217 M usaUSA
Pacira BioSciences Pacira BioSciences
PCRX
$ 26.35 0.08 % $ 1.17 B usaUSA
PetIQ PetIQ
PETQ
- 1.64 % $ 400 M usaUSA
ProPhase Labs ProPhase Labs
PRPH
- - $ 5.07 M usaUSA
Radius Health Radius Health
RDUS
- - $ 1.42 B usaUSA
Recro Pharma Recro Pharma
REPH
- -4.76 % $ 65.3 M usaUSA
Relmada Therapeutics Relmada Therapeutics
RLMD
$ 4.43 1.37 % $ 175 M usaUSA
Rockwell Medical Rockwell Medical
RMTI
$ 7.99 1.31 % $ 287 M usaUSA
SCYNEXIS SCYNEXIS
SCYX
$ 5.3 0.47 % $ 265 M usaUSA
Solid Biosciences Solid Biosciences
SLDB
$ 10.25 1.31 % $ 897 M usaUSA
Sonoma Pharmaceuticals Sonoma Pharmaceuticals
SNOA
$ 1.33 0.38 % $ 2.24 M usaUSA
Tricida Tricida
TCDA
- - $ 3.25 M usaUSA
Tilray Tilray
TLRY
$ 4.5 0.22 % $ 4.01 B canadaCanada
TherapeuticsMD TherapeuticsMD
TXMD
$ 2.21 0.22 % $ 25.6 M usaUSA
Veru Veru
VERU
$ 2.64 0.94 % $ 38.7 M usaUSA
Viatris Viatris
VTRS
$ 16.88 0.03 % $ 19.4 B usaUSA
cbdMD cbdMD
YCBD
$ 0.5 4.68 % $ 2.01 M usaUSA
Zomedica Corp. Zomedica Corp.
ZOM
- -0.21 % $ 98 M usaUSA